Reasons for Ibrutinib Discontinuation Linked With Length of CLL Survival

Patients with chronic lymphocytic leukemia who discontinue treatment with ibrutinib due to disease progression or transformation had significantly worse survival compared with patients who discontinued therapy because of intolerance.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news